NCT03421626 is a clinical trial of Xpert BCR-ABL Ultra in Leukemia, Myelogenous, Chronic, sponsored by Cepheid.

Who is sponsoring NCT03421626?

NCT03421626 is sponsored by Cepheid.

What drugs are being tested in NCT03421626?

Interventions in NCT03421626: Xpert BCR-ABL Ultra.

What condition does NCT03421626 study?

NCT03421626 studies Leukemia, Myelogenous, Chronic.

Is NCT03421626 still recruiting?

NCT03421626 is currently completed. Last updated 16 April 2019.

Last reviewed 2019-04-16 · How we verify

NCT03421626

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)

Completed Last updated 16 April 2019

What this trial tests

trial testing Xpert BCR-ABL Ultra in Leukemia, Myelogenous, Chronic in 266 participants. Completed in 20 August 2018.

Timeline

8 November 2017

Primary endpoint
20 August 2018

20 August 2018

Quick facts

Lead sponsor	Cepheid
Status	Completed
Study type	OBSERVATIONAL
Enrollment	266
Start date	8 November 2017
Primary completion	20 August 2018
Estimated completion	20 August 2018
Sites	7 locations across United States

Drugs / interventions tested

Xpert BCR-ABL Ultra

Conditions studied

Leukemia, Myelogenous, Chronic — all drugs for Leukemia, Myelogenous, Chronic →

Sponsor

Cepheid — full company profile →

Who can join

Adults 18 to 100, any sex, with Leukemia, Myelogenous, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Cepheid trials

Trials by the same sponsor.

NCT07520279 — Xpert® Tropical Fever Test on GeneXpert® Edge X System · enrolling by invitation
NCT07489846 — Xpert® ERP on the GeneXpert® System · completed
NCT07370454 — Xpert® Hemorrhagic Fever on the GeneXpert® Edge X System · completed
NCT06508996 — Xpert Hepatitis-C Virus (HCV) Test on the GeneXpert Xpress System · completed
NCT03664258 — A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Blad · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03421626 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cepheid
Last refreshed: 16 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03421626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing